Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU6-917P is a genomic pseudogene copy derived from the U6 small nuclear RNA gene family. U6 snRNA plays an essential role in the spliceosome, catalyzing intron removal from pre-mRNA in eukaryotic cells. Pseudogenes like RNU6-917P are formed by retrotransposition mechanisms (often mediated by LINE-1 elements) and do not encode functional RNAs or proteins. Pseudogenes are typically considered “dead” genes, lacking active transcription or protein-coding capacity. While some pseudogenes may be weakly transcribed and have roles in gene regulation or evolutionary genomic variation, there is no evidence that RNU6-917P itself acts as a therapeutic target, biological marker, or disease gene. If you require a structurally valid molecular target for drug discovery or biological research, “RNA, U6 small nuclear 917, pseudogene” should be excluded; instead, focus should be on the canonical U6 snRNA (if you're interested in RNA splicing) or other protein-coding genes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 917, pseudogene (RNU6-917P).